Curing root causes of chronic diseases and slowing down aging itself

Physics-enabled biotechnology company creating therapeutics against chronic diseases with a mission to slow down human aging itself

FOR PHARMA
FOR INVESTORS
Our collaborators
We are excited to announce
we entered into a research collaboration with

We Invite You to Discover Revolutionary Drugs Together

Gero.ai
We are scientists, this is why we value collaboration.

If you are a pharmaceutical company who is looking for novel drugs targeting age-related diseases, do not hesitate to contact us.

We’ve built Large Health Models (LHMs) using longitudinal real world human data

Our Approach
Unsupervised training methods that can predict future health outcomes akin to how Large Language Models (LLMs) can predict the next word in a sentence. Unlike LLMs, LHMs are physics-based and hence fully interpretable. In, and, in conjunction with genetics, LHMs revealing new treatments for chronic age-related diseases and new means of patient stratification.

Hacking aging

Aging is a natural part and the "last mile" of a human development program, and Gero pioneer ways to understand, measure, and, ultimately, control its progression.
Our Science
Longevity Biotech Gero Entered a Research Collaboration with Pfizer to Discover Potential Targets for Fibrotic Diseases
— "We are excited to work with Pfizer, one of the world’s leading biopharmaceutical companies, to potentially identify targets against fibrotic diseases, which have a large unmet need. We believe that combining our platform technology with Pfizer’s extensive disease expertise has the potential to identify high-value targets in this disease area."

Alex Kadet, CBO of Gero.
Collaborations
Gero in media